BISPECIFIC ANTIBODY OR ANTIBODY MIXTURE WITH COMMON LIGHT CHAINS

(19)

(11)

EP 3 243 840 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	26.08.2020 Bulletin 2020/35

(45)	Mention of the grant of the patent:
	15.07.2020 Bulletin 2020/29

(21)	Application number: 16734927.3

(22)	Date of filing: 08.01.2016

(51)

International Patent Classification (IPC):

C07K 16/46^(2006.01)
C07K 14/71^(2006.01)
C12N 15/12^(2006.01)
G01N 33/577^(2006.01)
A61P 35/00^(2006.01)

C07K 16/32^(2006.01)
C12N 15/13^(2006.01)
C12N 15/63^(2006.01)
A61K 39/395^(2006.01)

(86)	International application number:
	PCT/CN2016/070447

(87)	International publication number:
	WO 2016/110267 (14.07.2016 Gazette 2016/28)

(54)	BISPECIFIC ANTIBODY OR ANTIBODY MIXTURE WITH COMMON LIGHT CHAINS BISPEZIFISCHER ANTIKÖRPER ODER ANTIKÖRPERMISCHUNG MIT GEMEINSAMEN LEICHTEN KETTEN ANTICORPS BISPÉCIFIQUE OU MÉLANGE D'ANTICORPS AVEC DES CHAÎNES LÉGÈRES COMMUNES

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

08.01.2015 CN 201510008045

(43)	Date of publication of application:
	15.11.2017 Bulletin 2017/46

(73)	Proprietor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd.
	Suzhou, Jiangsu 215125 (CN)

(72)	Inventors:
	XU, Ting Suzhou Jiangsu 215125 (CN) XU, Tao Suzhou Jiangsu 215125 (CN) WANG, Xiaoxiao Suzhou Jiangsu 215125 (CN) LI, Qian Suzhou Jiangsu 215125 (CN) PANG, Minjie Suzhou Jiangsu 215125 (CN) ZHANG, Huimin Suzhou Jiangsu 215125 (CN) HAN, Li Suzhou Jiangsu 215125 (CN) ZHANG, Qingqing Suzhou Jiangsu 215125 (CN)

(74)	Representative: Weickmann & Weickmann PartmbB
	Postfach 860 820 81635 München 81635 München (DE)

(56)

References cited: :

WO-A1-2015/091738
CN-A- 103 796 678

CN-A- 1 668 636

J. JACKMAN ET AL: "Development of a Two-part Strategy to Identify a Therapeutic Human Bispecific Antibody That Inhibits IgE Receptor Signaling", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285, no. 27, 2 July 2010 (2010-07-02) , pages 20850-20859, XP055002016, ISSN: 0021-9258, DOI: 10.1074/jbc.M110.113910
LI B ET AL: "Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization", CANCER RESEARCH, AACR, US PHILADELPHIA, PA, vol. 73, no. 21, 1 November 2013 (2013-11-01), pages 6471-6483, XP002726071, ISSN: 1538-7445, DOI: 10.1158/0008-5472.CAN-13-0657 [retrieved on 2013-09-17]
FRANKLIN M C ET AL: "Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex", CANCER CELL, CELL PRESS, US, vol. 5, no. 4, 1 April 2004 (2004-04-01), pages 317-328, XP002372929, ISSN: 1535-6108, DOI: 10.1016/S1535-6108(04)00083-2
LIN, GUIGAO: 'Identification of natural bispecific antibody against hepatitis C virus NS3 and NS5 proteins C patients and the study of producing mechanism of the NS3/NS5 bispecific antibody' MEDICINE & PUBLIC HEALTH, CHINA DOCTORAL DISSERTATIONS FULL-TEXT DATABASE 15 February 2014, pages 21 - 26, XP009504575
LIN, GUIGAO: 'Identification of natural bispecific antibody against hepatitis C virus NS3 and NS5 proteins C patients and the study of producing mechanism of the NS3/NS5 bispecific antibody' MEDICINE & PUBLIC HEALTH, CHINA DOCTORAL DISSERTATIONS FULL-TEXT DATABASE 15 February 2014, XP009504575

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).